Free Trial

Sutro Biopharma (STRO) Competitors

Sutro Biopharma logo
$0.78 +0.04 (+5.90%)
Closing price 04:00 PM Eastern
Extended Trading
$0.77 -0.01 (-1.47%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STRO vs. IMMP, ACB, SGMT, TVGN, SLRN, CGC, NBTX, BTMD, MNPR, and SLS

Should you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Prima BioMed (IMMP), Aurora Cannabis (ACB), Sagimet Biosciences (SGMT), Semper Paratus Acquisition (TVGN), Acelyrin (SLRN), Canopy Growth (CGC), Nanobiotix (NBTX), biote (BTMD), Monopar Therapeutics (MNPR), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry.

Sutro Biopharma vs. Its Competitors

Sutro Biopharma (NASDAQ:STRO) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Sutro Biopharma currently has a consensus price target of $6.11, indicating a potential upside of 679.39%. Prima BioMed has a consensus price target of $7.00, indicating a potential upside of 311.76%. Given Sutro Biopharma's higher possible upside, equities analysts clearly believe Sutro Biopharma is more favorable than Prima BioMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sutro Biopharma
1 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25
Prima BioMed
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 5.9% of Sutro Biopharma shares are owned by insiders. Comparatively, 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Prima BioMed has lower revenue, but higher earnings than Sutro Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sutro Biopharma$62.04M1.07-$227.46M-$2.98-0.26
Prima BioMed$5.14M48.30-$28.01MN/AN/A

Sutro Biopharma has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Prima BioMed has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500.

In the previous week, Sutro Biopharma's average media sentiment score of 0.00 equaled Prima BioMed'saverage media sentiment score.

Company Overall Sentiment
Sutro Biopharma Neutral
Prima BioMed Neutral

Prima BioMed has a net margin of 0.00% compared to Sutro Biopharma's net margin of -373.66%. Prima BioMed's return on equity of 0.00% beat Sutro Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Sutro Biopharma-373.66% -347.60% -59.46%
Prima BioMed N/A N/A N/A

Summary

Prima BioMed beats Sutro Biopharma on 7 of the 12 factors compared between the two stocks.

Get Sutro Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STRO vs. The Competition

MetricSutro BiopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$62.57M$2.88B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.06%
P/E Ratio-0.267.5719.7120.50
Price / Sales1.07286.98435.75120.29
Price / CashN/A41.1936.8257.86
Price / Book1.457.487.985.56
Net Income-$227.46M-$55.04M$3.16B$248.40M
7 Day Performance15.37%5.44%3.69%6.04%
1 Month Performance-7.49%2.38%2.91%7.69%
1 Year Performance-74.19%5.53%34.30%20.97%

Sutro Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STRO
Sutro Biopharma
3.1919 of 5 stars
$0.78
+5.9%
$6.11
+679.4%
-74.6%$62.57M$62.04M-0.26240
IMMP
Prima BioMed
0.9837 of 5 stars
$1.64
flat
$7.00
+326.8%
-13.4%$239.50MN/A0.002,021Positive News
ACB
Aurora Cannabis
0.0982 of 5 stars
$4.24
+2.2%
N/A-8.1%$238.35M$343.29M38.551,130
SGMT
Sagimet Biosciences
2.4052 of 5 stars
$7.62
-3.2%
$26.60
+249.1%
+193.2%$233.71M$2M-4.338
TVGN
Semper Paratus Acquisition
3.9649 of 5 stars
$1.25
+0.8%
$10.00
+700.0%
+71.4%$229.86MN/A0.003Positive News
SLRN
Acelyrin
N/A$2.27
flat
$9.60
+322.9%
N/A$229.17MN/A-0.92135
CGC
Canopy Growth
2.8147 of 5 stars
$1.22
flat
$2.00
+63.9%
-81.1%$224.32M$225.65M-0.303,150News Coverage
NBTX
Nanobiotix
1.6904 of 5 stars
$4.73
+4.4%
$8.00
+69.1%
-13.1%$222.93M$39.18M0.00100News Coverage
Gap Up
BTMD
biote
3.251 of 5 stars
$4.02
-4.3%
$8.00
+99.0%
-46.0%$219.93M$197.19M6.59194News Coverage
Positive News
MNPR
Monopar Therapeutics
2.9043 of 5 stars
$35.78
+6.5%
$56.50
+57.9%
+933.2%$218.97MN/A-10.2810News Coverage
Analyst Forecast
SLS
SELLAS Life Sciences Group
0.1213 of 5 stars
$2.19
+12.3%
N/A+79.3%$218.52M$1M-5.7610News Coverage
High Trading Volume

Related Companies and Tools


This page (NASDAQ:STRO) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners